NCT06399861 Humidity in Incubators for Tiny Infants
| NCT ID | NCT06399861 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Extremely Premature Infant |
| Study Type | INTERVENTIONAL |
| Enrollment | 900 participants |
| Start Date | 2024-06-25 |
| Primary Completion | 2030-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 900 participants in total. It began in 2024-06-25 with a primary completion date of 2030-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to compare different supplemental incubator humidification strategies for infants \<25 weeks' gestation admitted to the neonatal intensive care unit (NICU). The study aims to compare higher (90%) and lower (70%) starting relative humidity (RH), as well as shorter (10 days) and longer (28 days) duration of humidity supplementation.
Eligibility Criteria
Inclusion Criteria: * Inborn infant of \<25 weeks' gestation admitted to the neonatal intensive care unit (NICU) Exclusion Criteria: * Infants with known congenital skin conditions * Outborn infants * Infants with unknown gestational age prior to birth * Infants with redirection of intensive care prior to study enrollment * Infants whose parents request not to participate
Contact & Investigator
Matthew A. Rysavy, MD, PhD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center, Houston
Frequently Asked Questions
Who can join the NCT06399861 clinical trial?
This trial is open to participants of all sexes, aged 0 Days or older, up to 1 Day, studying Extremely Premature Infant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06399861 currently recruiting?
Yes, NCT06399861 is actively recruiting participants. Contact the research team at Matthew.A.Rysavy@uth.tmc.edu for enrollment information.
Where is the NCT06399861 trial being conducted?
This trial is being conducted at Birmingham, United States, San Diego, United States, Columbus, United States, Columbus, United States and 5 additional locations.
Who is sponsoring the NCT06399861 clinical trial?
NCT06399861 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Matthew A. Rysavy, MD, PhD at The University of Texas Health Science Center, Houston. The trial plans to enroll 900 participants.